Skip to main content
SpringerLink
Log in

Treatment and Outcomes for Elderly Patients with Small Cell Lung Cancer

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

It is estimated that approximately half of the 500 000 people diagnosed with lung cancer worldwide every year are aged >70 years. Thus, this disease represents a major problem in the elderly and one that will indeed increase as the median age of the population increases. For small cell lung cancer (SCLC), which accounts for approximately 20% of cases of lung cancer, the primary treatment is chemotherapy and in the majority of cases the primary aim is to control the disease which generally would have spread beyond the lungs at the time of presentation. A small number of ‘standard’ chemotherapy regimens (combined with radiotherapy for patients with limited disease) have been shown to improve survival and quality of life and are widely used.

Much of the work investigating the relationship between age and treatment outcomes has been based on clinical trial data and may itself be inherently biased due to trial eligibility criteria excluding elderly patients. However, there is no good evidence that elderly patients fare worse with treatment than their younger counterparts in terms of response rates and survival. Nevertheless with increasing age comes increasing concomitant illnesses which may account for the widely observed increases in drug toxicity, and this may be the primary consideration in selecting the treatment option. Thus for many elderly patients, carboplatin/etoposide may be the treatment of choice because it is perhaps the least toxic of the standard regimens. Whatever regimen is chosen, the key to treatment effectiveness seems to be to deliver the first 3 or 4 cycles without delay or dosage reduction.

Although palliation of symptoms remains a major goal in the treatment of all patients with SCLC there is a dearth of data on whether elderly patients are equally well palliated as their younger counterparts.

There is no good evidence that age per se should be a factor in deciding whether patients should receive standard treatment rather than a more gentle approach, and more elderly patients should be included in clinical trials.

The key areas where more information is required regarding the treatment and outcomes of elderly patients with SCLC are the assessment of palliation, and comprehensive reviews of all patients diagnosed with the disease, not just those included in trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. Miller BA, Ries LAG, Hankey BF, et al. Cancer statistics review: 1973–1989. Maryland (MD): National Cancer Institute and National Institutes of Health; 1992. Publication No: 92-2789

    Google Scholar 

  2. Brown JS, Eraut D, Trask C, et al. Age and the treatment of lung cancer. Thorax 1996; 51: 564–8

    Article  PubMed  CAS  Google Scholar 

  3. Messeih AA, Schweitzer JM, Lipton A, et al. Addition of etoposide to cyclophosphamide, doxorubicin, and vincristine for remission induction and survival in patients with small cell lung cancer. Cancer Treat Rep 1987; 71: 61–6

    PubMed  CAS  Google Scholar 

  4. Abratt RP, Salton DGM, Malan JR, et al. A prospective randomised study in limited disease small cell carcinoma: doxorubicin and vincristine plus either cyclophosphamide or etoposide. Eur J Cancer 1995; 31A: 1637–9

    Article  PubMed  CAS  Google Scholar 

  5. Hong WK, Nicaise C, Lawson R, et al. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group. J Clin Oncol 1989; 7: 450–6

    PubMed  CAS  Google Scholar 

  6. Greco FA, Richardson RL, Schulman SF, et al. Treatment of oat cell carcinoma of the lung: complete remissions, acceptable complications, and improved survival. BMJ 1978; 2: 10–1

    Article  PubMed  CAS  Google Scholar 

  7. Bunn PA, Greco FA, Einhorn L. Cyclophosphamide, doxorubicin and etoposide as first-line therapy in the treatment of small-cell lung cancer. Semin Oncol 1986; 13Suppl. 3: 45–53

    PubMed  Google Scholar 

  8. Einhorn LH, Loehrer PJ. Hoosier Oncology Group Studies in extensive and recurrent small cell lung cancer. Semin Oncol 1995; 22Suppl. 2:28–31

    PubMed  CAS  Google Scholar 

  9. Kosmidis PA, Samantas E, Fountzilas G, et al. Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Semin Oncol 1994; 21Suppl. 6: 23–30

    PubMed  CAS  Google Scholar 

  10. Beith JM, Clarke SJ, Woods RL, et al. Long-term follow-up of a randomised trial of combined chemoradiotherapy induction treatment, with and without maintenance chemotherapy in patients with small cell carcinoma of the lung. Eur J Cancer 1996; 32A: 438–43

    Article  PubMed  CAS  Google Scholar 

  11. Ihde DC, Mulshine JL, Kramer BS, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small cell lung cancer. J Clin Oncol 1994; 12: 2022–34

    PubMed  CAS  Google Scholar 

  12. Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991; 83: 855–61

    Article  PubMed  CAS  Google Scholar 

  13. Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992; 10: 282–91

    PubMed  CAS  Google Scholar 

  14. Evans WK, Feld R, Murray N, et al. Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. Ann Intern Med 1987; 107: 451–8

    PubMed  CAS  Google Scholar 

  15. Smith IE, Evans BD, Gore ME, et al. Carboplatin (paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer. J Clin Oncol 1987; 5: 185–9

    PubMed  CAS  Google Scholar 

  16. Viren M, Liippo K, Ojala A, et al. Carboplatin and etoposide in extensive small cell lung cancer. Acta Oncol 1994; 33: 921–4

    Article  PubMed  CAS  Google Scholar 

  17. Bishop JF, Raghavan D, Stuart-Harris R, et al. Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer. J Clin Oncol 1987; 5: 1574–8

    PubMed  CAS  Google Scholar 

  18. Birch R, Weaver CH, Hainsworth JD, et al. A randomized study of etoposide and carboplatin with or without paclitaxel in the treatment of small cell lung cancer. Semin Oncol 1997; 24Suppl. 12: 135–7

    CAS  Google Scholar 

  19. Jones AL, Holborn J, Ashley S, et al. Effective new low toxicity chemotherapy with carboplatin, vinblastine and methotrexate for small cell lung cancer: a randomized trial against doxorubicin, cyclophosphamide and etoposide. Eur J Cancer 1991; 27: 866–70

    Article  PubMed  CAS  Google Scholar 

  20. Thatcher N, Sambrook RJ, Stephens RJ, et al. Dose intensification (DI) with G-CSF improves survival in small cell lung cancer (SCLC): results of a randomized trial [abstract 1754]. Proc Am Soc Clin Oncol 1997; 17: 456a

    Google Scholar 

  21. Matelski HW, Lokich JJ, Huberman MS, et al. Adriamycin, cyclophosphamide, and etoposide (VP-16-213) in extensive-stage small cell lung cancer. Am J Clin Oncol 1984; 7: 729–32

    Article  PubMed  CAS  Google Scholar 

  22. Jackson DV, Zekan PJ, Caldwell RD, et al. VP-16-213 in combination chemotherapy with chest irradiation for small-cell lung cancer: a randomized trial of the Piedmont Oncology Association. J Clin Oncol 1984; 2: 1343–51

    PubMed  Google Scholar 

  23. Goodman GE, Crowley JJ, Blasko JC, et al. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group study. J Clin Oncol 1990; 8: 39–47

    PubMed  CAS  Google Scholar 

  24. Murray N, Shah A, Osoba D, et al. Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer. J Clin Oncol 1991; 9: 1632–8

    PubMed  CAS  Google Scholar 

  25. Murray N, Livingstone R, Shepherd F, et al. Randomized study of CODE versus alternating CAV/EP for extensive stage small cell lung cancer: an intergroup study of the National Cancer Institute of Canada Clinical Trials group and the Southwest Oncology Group. J Clin Oncol 1999; 17: 2300–8

    PubMed  CAS  Google Scholar 

  26. Fukuoka M, Masuda N, Negoro S, et al. CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. Br J Cancer 1997; 75: 306–9

    Article  PubMed  CAS  Google Scholar 

  27. Hainsworth JD, Hopkins LG, Thomas M, Greco FA. Paclitaxel, carboplatin and extended schedule oral daily etoposide for small cell lung cancer. Oncology 1998; 12 (1 Suppl. 2): 31–5

    PubMed  CAS  Google Scholar 

  28. Hainsworth JD, Greco FA. The current role and future prospects of paclitaxel in the treatment of small cell lung cancer. Semin Oncol 1999; 26Suppl. 2: 60–6

    PubMed  CAS  Google Scholar 

  29. Murray N. Importance of dose and dose intensity in the treatment of small-cell lung cancer. Cancer Chemother Pharmacol 1997; 40 Suppl.: S58–63

    Article  PubMed  Google Scholar 

  30. Amagada R, Le Chevalier T, Pignon JP, et al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 1993; 329: 1848–52

    Article  Google Scholar 

  31. Pignon JP, Amagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992; 327: 1618–24

    Article  PubMed  CAS  Google Scholar 

  32. Murray N, Coy P, Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J Clin Oncol 1993; 11: 336–44

    PubMed  CAS  Google Scholar 

  33. Jeremic B, Shibamoto Y, Acimovic L, et al. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J Clin Oncol 1997; 15: 893–900

    PubMed  CAS  Google Scholar 

  34. Work E, Nielsen OS, Bentzen SM, et al. Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. J Clin Oncol 1997; 15: 3030–7

    PubMed  CAS  Google Scholar 

  35. Perry MC, Eaton WL, Propert KJ, et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 1987; 316: 912–8

    Article  PubMed  CAS  Google Scholar 

  36. Goto K, Nishiwaki Y, Takada M, et al. Final results of a phase III study of concurrent vs sequential thoracic radiotherapy (TRT) in combination with cisplatin (P) and etoposide (E) for limited stage small cell lung cancer (LD SCLC): the Japan Clinical Oncology Group (JCOG) study [abstract 1805]. Proc Am Soc Clin Oncol 1999; 18: 468a

    Google Scholar 

  37. Auperin A, Amagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small cell lung cancer in complete remission. N Engl J Med 1999; 341: 476–84

    Article  PubMed  CAS  Google Scholar 

  38. Cull A, Gregor A, Hopwood P, et al. Neurological and cognitive impairment in long term survivors of small cell lung cancer. Eur J Cancer 1994; 30A: 1067–74

    Article  PubMed  CAS  Google Scholar 

  39. Andersen M, Kristjansen PE, Hansen HH. Second-line chemotherapy in small cell lung cancer. Cancer Treat Rev 1990; 17: 427–36

    Article  PubMed  CAS  Google Scholar 

  40. Ardizzoni A, Hansen H, Dombernowsky P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refectory and sensitive disease. J Clin Oncol 1997; 15: 2090–6

    PubMed  CAS  Google Scholar 

  41. Tummarello D, Guidi F, Torresi U, et al. Teniposide (VM26) as second-line treatment for small cell lung cancer. Anticancer Res 1990; 10: 397–9

    PubMed  CAS  Google Scholar 

  42. Falk SJ, Maughan TS, Laurence VM, et al. Phase II study of carboplatin and adriamycin as second line chemotherapy in small cell lung cancer. Clin Oncol (R Coll Radiol) 1993; 5: 85–8

    Article  CAS  Google Scholar 

  43. Postmus PE, Smit EF, Berendsen HH, et al. Second-line carboplatin-based chemotherapy small cell lung cancer: the Groningen experience. Semin Oncol 1992; 19Suppl. 2: 17–23

    PubMed  CAS  Google Scholar 

  44. Ebi N, Kubota K, Nishiwaki, et al. Second-line chemotherapy for relapsed small cell lung cancer. Jpn J Clin Oncol 1997; 27: 166–9

    Article  PubMed  CAS  Google Scholar 

  45. Dajczman E, Fu LY, Small D, et al. Treatment of small cell lung carcinoma in the elderly. Cancer 1996; 77: 2032–8

    Article  PubMed  CAS  Google Scholar 

  46. Tebbutt NC, Snyder RD, Burns WI. An analysis of the outcomes of treatment of small cell lung cancer in the elderly. Aust N Z J Med 1997; 27: 160–4

    Article  PubMed  CAS  Google Scholar 

  47. Shepherd FA, Amdemichael E, Evans WK, et al. Treatment of small cell lung cancer in the elderly. J Am Geriatr Soc 1994; 42: 64–70

    PubMed  CAS  Google Scholar 

  48. Clamon GH, Audeh MW, Pinnick S. Small cell lung carcinoma in the elderly. J Am Geriatr Soc 1982; 30: 299–302

    PubMed  CAS  Google Scholar 

  49. Siu LL, Shepherd FA, Murray N, et al. Influence of age on the treatment of limited-stage small-cell lung cancer. J Clin Oncol 1996; 14: 821–8

    PubMed  CAS  Google Scholar 

  50. Paccagnella A, Favaretto A, Cipriani A, et al. Treatment of small cell lung cancer (SCLC) in elderly patients [abstract 1164]. Proc Am Soc Clin Oncol 1996; 15: 387

    Google Scholar 

  51. Medical Research Council Lung Cancer Working Party. Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. Br J Cancer 1996; 73: 406–13

    Article  Google Scholar 

  52. Medical Research Council Lung Cancer Working Party. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Lancet 1996; 348: 563–6

    Article  Google Scholar 

  53. De Haes JCJ, Knippenberg FCE, Neijt JP. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer 1990; 62: 1034–8

    Article  PubMed  Google Scholar 

  54. Teeter SM, Holmes FF, McFarlane MJ. Lung carcinoma in the elderly population. Cancer 1987; 60: 1331–6

    Article  PubMed  CAS  Google Scholar 

  55. Suen KC, Lau LL, Yermakov V. Cancer and old age: an autopsy study of 3535 patients over 65 years old. Cancer 1974; 3: 1164–8

    Article  Google Scholar 

  56. Holmes FF. Clinical evidence for a change in tumor aggressiveness with age. Semin Oncol 1989; 16: 34–40

    PubMed  CAS  Google Scholar 

  57. O’Rourke MA, Feussner JR, Feigl P, et al. Age trends of lung cancer stage at diagnosis. JAMA 1987; 258: 921–6

    Article  PubMed  Google Scholar 

  58. Muers MF, Haward RA. Management of lung cancer. Thorax 1996; 51: 557–60

    Article  PubMed  CAS  Google Scholar 

  59. Guadagnoli E, Weitberg A, Mor V, et al. The influence of patient age on the diagnosis and treatment of lung and colorectal cancer. Arch Intern Med 1990; 150: 1485–90

    Article  PubMed  CAS  Google Scholar 

  60. Slevin ML, Stubbs L, Plant HJ, et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses and general public. BMJ 1990; 300: 1458–60

    Article  PubMed  CAS  Google Scholar 

  61. Raby B, Pater J, Mackillop WJ. Does knowledge guide practice? Another look at the management of non-small cell lung cancer. J Clin Oncol 1995; 13: 1904–11

    PubMed  CAS  Google Scholar 

  62. Kennedy BJ. Aging and cancer. J Clin Oncol 1988; 6: 1903–11

    PubMed  CAS  Google Scholar 

  63. Hrushesky WJM, Slump W, Kennedy BJ. Lack of age-dependent cisplatin neurotoxicity. Am J Med 1984; 76: 579–84

    Article  PubMed  CAS  Google Scholar 

  64. Walsh SJ, Begg CB, Carbone PP. Cancer chemotherapy in the elderly. Semin Oncol 1989; 16: 66–75

    PubMed  CAS  Google Scholar 

  65. Nerenz DR, Love RR, Leventhal H, et al. Psychosocial consequences of cancer chemotherapy for elderly patients. Health Services Res 1986; 20: 961–76

    CAS  Google Scholar 

  66. Ganz PA, Schag CC, Heinrich RL. The psychosocial impact of cancer on the elderly: a comparison with younger patients. J Am Geriatr Soc 1985; 33: 429–35

    PubMed  CAS  Google Scholar 

  67. Silvestri G, Pritchard R, Welch HG. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 1998; 317: 771–5

    Article  PubMed  CAS  Google Scholar 

  68. Goss GD, Logan D, Maroun J, et al. Chemotherapy in elderly patients with small cell lung cancer (SCLC) [abstract 969]. Proc Am Soc Clin Oncol 1992; 11: 290

    Google Scholar 

  69. Keane M, Carney DN. Treatment of elderly patients with small cell lung cancer. Lung Cancer 1993; 9Suppl. 1: S91–8

    Article  Google Scholar 

  70. Zagonel V, Tirelli U, Serraino D, et al. The aged patient with lung cancer: management recommendations. Drugs Aging 1994; 4: 34–46

    Article  PubMed  CAS  Google Scholar 

  71. Hansen M, Hirsch F, Dombernowsky P, et al. Treatment of small cell anaplastic carcinoma of the lung with the oral solution of VP-16-213 (NSC 141540, 4′demethlepipodophyllotoxin 9-(4, 6-0-ethylidene-β-D-glucopyranoside). Cancer 1977; 40: 633–7

    Article  PubMed  CAS  Google Scholar 

  72. Dorward AJ. A prospective study of low dose oral etoposide in poor prognosis small cell lung cancer (SCLC) [abstract]. Cancer Treat Res 1991; 7: 111

    Google Scholar 

  73. Postmus PE, Smit EF, Berendsen HH. Phase II study of daily oral etoposide (OE) on a 5-week schedule in elderly patients (pts) with small cell lung cancer (SCLC) [abstract]. Ann Oncol 1990; 1 Suppl.: 54

    Google Scholar 

  74. Cavalli F, Sonntag RW, Jungi F, et al. VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomised trial using three dosage schedules. Cancer Treat Rep 1978; 62: 473–5

    PubMed  CAS  Google Scholar 

  75. Slevin ML, Clark PI, Joel S, et al. Arandomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 1989; 7: 1333–40

    PubMed  CAS  Google Scholar 

  76. Smit EF, Carney DN, Harford P, et al. A phase II study of oral etoposide in elderly patients with small cell lung cancer. Thorax 1989; 44: 631–3

    Article  PubMed  CAS  Google Scholar 

  77. Carney DN, Byrne A. Etoposide in the treatment of elderly/poor-prognosis patients with small-cell lung cancer. Cancer Chemother Pharmacol 1994; 34 Suppl.: S96–100

    Article  PubMed  Google Scholar 

  78. Bork E, Hansen M, Dombernowsky P, et al. Teniposide (VM-26), an overlooked highly active agent in small-cell lung cancer: results of a phase II trial in untreated patients. J Clin Oncol 1986; 4: 524–7

    PubMed  CAS  Google Scholar 

  79. Holoye PY, Winn RJ, Craig K, et al. Phase II study of teniposide in small cell bronchogenic carcinoma [abstract 946]. Proc Am Soc Clin Oncol 1989; 8: 243

    Google Scholar 

  80. Tummarello D, Isidori P, Pasini F, et al. Teniposide as single drug therapy for elderly patients affected by small cell lung cancer. Eur J Cancer 1992; 28A: 1081–4

    Article  PubMed  CAS  Google Scholar 

  81. Cerny T, Pedrazzini A, Joss RA, et al. Unexpected high toxicity in a phase II study of teniposide (VM-26) in elderly patients with untreated small cell lung cancer (SCLC). Eur J Cancer 1988; 24: 1791–4

    Article  CAS  Google Scholar 

  82. Giaccone G, Donadio M, Bonardi G, et al. Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy. J Clin Oncol 1988; 6: 1264–70

    PubMed  CAS  Google Scholar 

  83. Cascinu S, Del Ferro E, Ligi M, et al. The clinical impact of teniposide in the treatment of elderly patients with small-cell lung cancer. Am J Clin Oncol 1997; 20: 477–8

    Article  PubMed  CAS  Google Scholar 

  84. Manegold C, Loechner S, Bachmann P, et al. Oral ifosphamide in elderly and/or unfit patients with small-cell lung cancer (SCLC): a phase II study [abstract]. Ann Oncol 1992; 3Suppl. 5:38

    Google Scholar 

  85. Quoix EA, Giaccone G, Jassem J, et al. Epirubicin in previously untreated patients with small cell lung cancer: a phase II study by the EORTC lung cancer cooperative group. Eur J Cancer 1992; 28A: 1667–70

    Article  PubMed  CAS  Google Scholar 

  86. Smith IE, Evans BD. Carboplatin (JM8) as a single agent and in combination in the treatment of small cell lung cancer. Cancer Treat Rev 1985; 12Suppl. A: 73–5

    Article  PubMed  Google Scholar 

  87. Bork E, Ersboll J, Dombernowsky P, et al. Teniposide and etoposide in previously untreated small-cell lung cancer: a randomized study. J Clin Oncol 1991; 9: 1627–31

    PubMed  CAS  Google Scholar 

  88. Ettinger D, Finkelstein D, Ritch P, et al. Randomized trial of single agents vs combination chemotherapy in extensive stage small cell lung cancer (SCLC) [abstract 988]. Proc Am Soc Clin Oncol 1992; 11: 295

    Google Scholar 

  89. Souhami RL, Spiro SG, Rudd RM, et al. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst 1997; 89: 577–80

    Article  PubMed  CAS  Google Scholar 

  90. Byrne A, Carney DN. Small cell lung cancer in the elderly. Semin Oncol 1994; 21Suppl. 6: 43–8

    PubMed  CAS  Google Scholar 

  91. Evans WK, Radwi A, Tomiak E, et al. Oral etoposide and carboplatin: effective therapy for elderly patients with small cell lung cancer. Am J Clin Oncol 1995; 18: 149–55

    Article  PubMed  CAS  Google Scholar 

  92. Matsui K, Masuda N, Takada M, et al. Phase II trial of carboplatin (CBDCA) plus oral etoposide (ETP) for elderly patients with small cell lung cancer (SCLC) [abstract 1157]. Proc Am Soc Clin Oncol 1996; 15: 385

    Google Scholar 

  93. Michel G, Leyvraz S, Bauer J, et al. Weekly carboplatin and VM-26 for elderly patients with small-cell lung cancer. Ann Oncol 1994; 5: 369–70

    PubMed  CAS  Google Scholar 

  94. Allan SG, Gregor A, Cornbleet MA, et al. Phase II trial of vindesine and VP16-213 in the palliation of poor-prognosis patients and elderly patients with small cell lung cancer. Cancer Chemother Pharmacol 1984; 13: 106–8

    Article  PubMed  CAS  Google Scholar 

  95. Westeel V, Murray N, Gelmon K, et al. New combination of the old drugs for elderly patients with small-cell lung cancer: a phase II study of the PAVE regimen. J Clin Oncol 1998; 16: 1940–7

    PubMed  CAS  Google Scholar 

  96. Radford JA, Ryder WDJ, Dodwell D, et al. Predicting septic complications of chemotherapy: an analysis of 382 patients treated for small cell lung cancer without dose reduction after major sepsis. Eur J Cancer 1993; 29A: 81–6

    Article  Google Scholar 

  97. Stephens RJ, Girling DJ, Machin D. Treatment-related deaths in small cell lung cancer trials: can patients at risk be identified? Lung Cancer 1994; 11: 259–74

    Article  PubMed  CAS  Google Scholar 

  98. Lyman GH, Lyman CG, Sanderson RA, et al. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 1993; 85: 488–93

    Article  PubMed  CAS  Google Scholar 

  99. Nichols CR, Fox EP, Roth BJ, et al. Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor. J Clin Oncol 1994; 12: 1245–50

    PubMed  CAS  Google Scholar 

  100. Raghavan D, Bishop JF, Stuart-Harris R, et al. Carboplatin-containing regimens for small call lung cancer: implications for management in the elderly. Semin Oncol 1992; 1Suppl. 2: 12–6

    Google Scholar 

  101. Matsui K, Takada M, Masuda N, et al. Pilot study of carboplatin (CBDCA) calculated by Egorin’s formula plus oral etoposide (ETP) for elderly patients with small cell lung cancer (SCLC) [abstract 1179]. Proc Am Soc Clin Oncol 1994; 13: 352

    Google Scholar 

  102. Skarlos DV, Samantas E, Kosmidis P, et al. Randomized comparison of etoposide-cisplatin vs etoposide-carboplatin and irradiation in small-cell lung cancer: a Hellenic Cooperative Oncology Group study. Ann of Oncol 1994; 5: 601–7

    CAS  Google Scholar 

  103. Bishop JF. Carboplatin/etoposide in small cell lung cancer. Oncology 1992; 49Suppl. 1: 11–8

    Article  PubMed  Google Scholar 

  104. Shibata K, Nakatsumi Y, Kasahara K, et al. Analysis of thrombocytopenia due to carboplatin combined with etoposide in elderly patients with lung cancer. J Cancer Res Clin Oncol 1996; 122: 437–42

    Article  PubMed  CAS  Google Scholar 

  105. Murray N, Grafton C, Shah A, et al. Abbreviated treatment for elderly, infirm, or noncompliant patients with limited stage small-cell lung cancer. J Clin Oncol 1998; 16: 3323–8

    PubMed  CAS  Google Scholar 

  106. Jeremic B, Shibamoto Y, Acimovic L, et al. Carboplatin, etoposide and accelerated hyperfractionated radiotherapy for elderly patients with limited small cell lung carcinoma: a phase II study. Cancer 1998; 82: 836–41

    Article  PubMed  CAS  Google Scholar 

  107. Turrisi A, Kim K, Sause W, et al. Observations after 5-year follow-up of intergroup trial 0096: 4 cycles of cisplatin (P) etoposide (E) and concurrent 45 GY thoracic radiotherapy (TRT) given in daily (QD) or twice-daily fractions followed by 25 GY PCI. Survival differences and patterns of failure [abstract 1757]. Proc Am Soc Clin Oncol 1998; 17: 457a

    Google Scholar 

  108. Yuen A, Zou G, Turissi A, et al. Similar outcome of elderly patients in intergroup trial 0096: cisplatin (P), etoposide (E), and thoracic radiotherapy (TRT) administered once (QD) or twice daily (BID) in limited stage small cell lung cancer (SCLC) [abstract 1803]. Proc Am Soc Clin Oncol 1999; 18: 467a

    Google Scholar 

  109. Quon H, Shepherd FA, Payne DG, et al. The influence of age on the delivery, tolerance, and efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer. Int J Radiat Oncol Biol Phys 1999; 43: 39–45

    Article  PubMed  CAS  Google Scholar 

  110. Zagonel V, Fratino L, Sacco C, et al. Reducing chemotherapy-associated toxicity in elderly cancer patients. Cancer Treat Rev 1996; 22: 223–44

    Article  PubMed  CAS  Google Scholar 

  111. Shank WA, Balducci L. Recombinant hemopoietic growth factors: comparative hemopoietic response in younger and older subjects. J Am Geriatr Soc 1992; 40: 151–4

    PubMed  Google Scholar 

  112. Maslak P, Nimer SD. The efficacy of IL-3, SCF, IL-6 and IL-11 in treating thrombocytopenia. Semin Haematol 1998; 35: 253–60

    CAS  Google Scholar 

  113. Abels RI. Use of recombinant human erythropoietin in the treatment of anaemia in patients who have cancer. Semin Oncol 1992; 19: 29–35

    PubMed  CAS  Google Scholar 

  114. Caprizzi RL. Clinical status and optimal use of amifostine. Oncology 1999; 13: 47–59

    Google Scholar 

  115. Markman M. Amifostine in reducing cisplatin toxicity. Semin Oncolol 1998; 25: 522–4

    CAS  Google Scholar 

  116. Niiranen A, Kajanti M, Tammilehto L, et al. The clinical effect of medroxyprogesterone (MPA) in elderly patients with lung cancer. Am J Clin Oncol 1990; 13: 113–6

    Article  PubMed  CAS  Google Scholar 

  117. Begg CB, Carbone PP. Clinical trials and drug toxicity in the elderly: the experience of the Eastern Cooperative Oncology Group. Cancer 1983; 52: 1986–92

    Article  PubMed  CAS  Google Scholar 

  118. Ohnoshi T, Ueoka H, Hino N, et al. Treatment of small cell lung cancer in the elderly: the progress and limitation of chemotherapy. Nihon Kyobo Shikkan Gakkai Zasshi 1992; 30: 216–23

    CAS  Google Scholar 

  119. Nou E. Full chemotherapy in elderly patients with small cell bronchial carcinoma. Acta Oncol 1996; 35: 399–406

    Article  PubMed  CAS  Google Scholar 

  120. Kelly P, O’Brien AAJ, Daly P, et al. Small-cell lung cancer in elderly patients: the case for chemotherapy. Age Aging 1991; 20: 19–22

    Article  CAS  Google Scholar 

  121. Vincent MD, Ashley SE, Smith IE. Prognostic factors in small cell lung cancer: a simple prognostic index is better than conventional staging. Eur J Cancer Clin Oncol 1987; 23: 1589–99

    Article  PubMed  CAS  Google Scholar 

  122. Cerny T, Blair V, Anderson H, et al. Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer 1987; 39: 146–9

    Article  PubMed  CAS  Google Scholar 

  123. Rawson NSB, Peto J. An overview of prognostic factors in small cell lung cancer: a report from the subcommittee for the management of lung cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer 1990; 61: 597–604

    Article  PubMed  CAS  Google Scholar 

  124. Sagman U, Maki E, Evans WK, et al. Small-cell carcinoma of the lung: derivation of a prognostic staging system. J Clin Oncol 1991; 9: 1639–49

    PubMed  CAS  Google Scholar 

  125. Medical Research Council Lung Cancer Working Party. A randomised trial of three or six courses of etoposide cyclophosphamide, methotrexate and vincristine or six courses of etoposide and ifosphamide in small cell lung cancer (SCLC) I: survival and prognostic factors. Br J Cancer 1993; 68: 1150–6

    Article  Google Scholar 

  126. Kawahara M, Fukuoka M, Saijo N, et al. Prognostic factors and prognostic staging system for small cell lung cancer. Jpn J Clin Oncol 1997; 27: 158–65

    Article  PubMed  CAS  Google Scholar 

  127. Maestu I, Pastor M, Gomez-Codina J, et al. Pretreatment prognostic factors for survival in small-cell lung cancer: a new prognostic index and validation of three known prognostic indicies on 341 patients. Ann Oncol 1997; 8: 547–53

    Article  PubMed  CAS  Google Scholar 

  128. Tamura M, Ueoka H, Kiura K, et al. Prognostic factors of small-cell lung cancer in Okayama Lung Cancer Study Group trials. Acta Med Okayama 1998; 52: 105–11

    PubMed  CAS  Google Scholar 

  129. Albain KS, Crowley JJ, LeBlanc M, et al. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2580-patient Southwest Oncology Group data base. J Clin Oncol 1990; 8: 1563–74

    PubMed  CAS  Google Scholar 

  130. Spiegelman D, Maurer LH, Ware JH, et al. Prognostic factors in small-cell carcinoma of the lung: an analysis of 1521 patients. J Clin Oncol 1989; 7: 344–54

    PubMed  CAS  Google Scholar 

  131. Osterlind K, Andersen PK. Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res 1986; 46: 4189–94

    PubMed  CAS  Google Scholar 

  132. Maurer LH, Pajak TF. Prognostic factors in small cell carcinoma of the lung: a Cancer and Leukemia Group B study. Cancer Treat Rep 1981; 65: 767–74

    PubMed  CAS  Google Scholar 

  133. Wolf M, Holle R, Hans K, et al. Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): the role of sex as a predictor for survival. Br J Cancer 1991; 63: 986–92

    Article  PubMed  CAS  Google Scholar 

  134. Stephens RJ, Hopwood P, Girling DJ. Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise. Br J Cancer 1999; 79: 538–44

    Article  PubMed  CAS  Google Scholar 

  135. Poplin E, Thompson B, Whitacre M, et al. Small cell carcinoma of the lung: influence of age on treatment outcome. Cancer Treat Rep 1987; 71: 291–6

    PubMed  CAS  Google Scholar 

  136. Armitage JO, Potter JF. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age. J Am Geriatr Soc 1984; 32: 269–73

    PubMed  CAS  Google Scholar 

  137. Balducci L, Parker M, Sexton W, et al. Pharmacology of antineoplastic agents in the elderly patient. Semin Oncolol 1989; 16: 76–84

    CAS  Google Scholar 

  138. Mitchell EP. Gastrointestinal toxicity of chemotherapeutic agents. Semin Oncolol 1992; 19: 566–79

    CAS  Google Scholar 

  139. Tuxen MK, Hansen SW. Neurotoxicity secondary to antineoplastic drugs. Cancer Treat Rev 1994; 20: 191–214

    Article  PubMed  CAS  Google Scholar 

  140. Thyss A, Saudes L, Otto J, et al. Renal tolerance of cisplatin in patients more than 80 years old. J Clin Oncol 1994; 12: 2121–5

    PubMed  CAS  Google Scholar 

  141. Patterson WP, Reams GP. Renal toxicities of chemotherapy. Semin Oncolol 1992; 19: 521–8

    CAS  Google Scholar 

  142. Findlay MPN, Griffin AM, Raghavan D, et al. Retrospective review of chemotherapy for small cell lung cancer in the elderly: does the end justify the means? Eur J Cancer 1991; 27: 1597–601

    Article  PubMed  CAS  Google Scholar 

  143. Joel SP, Clark PI, Slevin ML. Risk factors which predict for haematological toxicity with etoposide [abstract B4]. Br J Cancer 1992; 65Suppl. 16: 11

    Google Scholar 

  144. Fretwell M. The consensus conference on Comprehensive Geriatric Assessment: a dialogue is the beginning of consensus. J Am Geriatr Soc 1988; 36: 377–9

    PubMed  CAS  Google Scholar 

  145. Monfardini S, Ferrucci L, Fratino L, et al. Validation of a Multidimensional Evaluation Scale for use in elderly cancer patients. Cancer 1996; 77: 395–401

    Article  PubMed  CAS  Google Scholar 

  146. Morittu L, Earl HM, Souhami RL, et al. Patients at risk of chemotherapy-associated toxicity in small cell lung cancer. Br J Cancer 1989; 59: 801–4

    Article  PubMed  CAS  Google Scholar 

  147. Samet J, Hunt WC, Key C, et al. Choice of cancer therapy varies with age of patient. JAMA 1986; 255: 3385–90

    Article  PubMed  CAS  Google Scholar 

  148. Sambrook RJ, Girling DJ. A national survey of chemotherapy (CT) in small cell lung cancer (SCLC) [abstract S54]. Thorax 1999; 54Suppl. 3: A14

    Google Scholar 

  149. Zagonel V, Pinto A, Serraino D, et al. Lung cancer in the elderly. Cancer Treat Rev 1994; 20: 315–29

    Article  PubMed  CAS  Google Scholar 

  150. Trimble EL, Carter CL, Cain D, et al. Representation of older patients in cancer treatment trials. Cancer 1994; 74 (7 Suppl.): 2208–14

    Article  PubMed  CAS  Google Scholar 

  151. Hutchins LF, Unger JM, Crowley JJ, et al. Under-representation of patients 65 year of age or older in cancer treatment trials. N Engl J Med 1999; 341: 2061–7

    Article  PubMed  CAS  Google Scholar 

  152. Brundage MD, Davidson JR, Mackillop WJ. Trading treatment toxicity for survival in locally advanced non-small lung cancer. J Clin Oncol 1997; 15: 330–40

    PubMed  CAS  Google Scholar 

  153. Zagonel V, Tirelli U. Age as a risk factor for inadequate treatment [letter]. JAMA 1988; 259: 41

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Division, Medical Research Council Clinical Trials Unit, 222 Euston Road, London, NW1 2DA, England

    Richard J. Stephens

  2. Department of Medicine, Division of Medical Oncology, Vanderbilt University Medical School, Nashville, Tennessee, USA

    David H. Johnson

Authors
  1. Richard J. Stephens
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David H. Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard J. Stephens.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stephens, R.J., Johnson, D.H. Treatment and Outcomes for Elderly Patients with Small Cell Lung Cancer. Drugs & Aging 17, 229–247 (2000). https://doi.org/10.2165/00002512-200017030-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200017030-00006

Keywords

Search

Navigation